DNDN halted after close................

Discussion in 'Stocks' started by flytiger, Apr 13, 2009.

  1. they are dropping a bomb, and releasing results before the open.

    If it's positive, and judging by stock action it is, there is going to be a lot of blown out accounts. DNDN was a longtime sho stock, and could have a multiple of the float short.

    Maybe these idiots will decide the risk here isn't worth it, and start turning down these flybynight offshore funds as "customers".
  2. i thought the drug did not work...:confused:
  3. Rumored the last time that an FDA panel member had a conflict of interest.

    any positive news tomorrow should make this thing scream. I'm no researcher. I trade paper (in electronic form).
  4. $100 in your paypal if you're right tiger.... how much in my account if you're wrong?
  5. Oh Snap! looks like DNDN pulled a big one up the shorties ... Even the vaseline sold at costco might not be enough on this one ...
  6. To every swinging dick who ever said to me.........."name one company.........."

    go fuck yourselves.

    Hear Huckman? "shockingly, the FDA said, go back to the drawing board."

    I wonder how that happened? Wouldn't have been a well - placed envelope, would it?

    Beyond reprehensible. Truly, and I used to love it. Wall St. should just disappear from the face of the earth.

    This will wipe out a broker or two.
  7. zdreg


    between the lawyers and the traders (in electronic form) both of whom are paper shufflers the US is losing its economic supremacy. this is a bad future to look forward to.
  8. How do I get you my paypal info?:D

    Do me a favor. Send a hundred bucks to St. Jude Medical.
  9. rickf


    PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study

    * Dendreon Corp.

    - Study Meets Primary Endpoint Showing Statistically Significant Improvement in Overall Survival -

    SEATTLE, April 14 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN - News) announced today that the pivotal Phase 3 IMPACT study of PROVENGE® (sipuleucel-T) in men with advanced prostate cancer met its primary endpoint of improving overall survival compared to a placebo control. The magnitude of the survival difference observed in the intent to treat population resulted in the study successfully achieving the pre-specified level of statistical significance defined by the study's design. The safety profile of PROVENGE appeared to be consistent with prior trials.

    The 512-patient, multi-center, randomized, double-blind, placebo-controlled IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) study enrolled men with metastatic androgen-independent prostate cancer was conducted under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration (FDA).

    PROVENGE is Dendreon's investigational product candidate for men with advanced prostate cancer and may represent the first in a new class of active cellular immunotherapies specifically designed to engage the patient's own immune system against cancer.

    Detailed results from the IMPACT study will be presented during a plenary session at the American Urological Association's Annual Meeting in Chicago on Tues., Apr. 28 at 2:20 pm CT.

    "Survival is the gold standard outcome for oncology clinical trials, and overall survival was the primary endpoint of the IMPACT trial. The positive results from this landmark study provide confirmatory evidence demonstrating that treatment with PROVENGE may prolong survival," said Mitchell H. Gold, M.D., president and chief executive officer of Dendreon. "We are immensely grateful to our clinical investigators and the more than 1,000 men with advanced prostate cancer who have participated in our studies over the last decade and whose courage and contribution have significantly advanced the understanding and treatment of prostate cancer and the potential role of cancer immunotherapies."

    "The successful outcome from the Phase 3 IMPACT study provides validation of the long-pursued goal of harnessing the human immune system against a patient's own cancer," continued Dr. Gold.

    Because the data meet the criteria and specifications outlined in its Special Protocol Assessment (SPA) agreement with the FDA, Dendreon intends to file an amendment to its existing Biologic License Application (BLA) in the fourth quarter of this year to gain licensure of PROVENGE.

    Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than one million men in the United States have prostate cancer, with an estimated 186,320 new cases and approximately 28,660 men who were expected to die from the disease in 2008. Currently there are limited treatment options for men with advanced, metastatic prostate cancer.
  10. rickf


    I played DNDN in 2007 - to this date it's the best options speculation I ever did and I'll never forget what that Mother of All Short Squeezes gave to me. :)

    This time, I sat on the sidelines and watched. If it skyrockets, congrats to the longs; I had my fun with DNDN in '07. Not going to press my luck!
    #10     Apr 14, 2009